A Phase 2, Single-arm Pathologist-blinded 48-week Study Using Liver Biopsy Specimens to Assess Copper Concentration and Histopathologic Changes in ALXN1840-treated Patients With Wilson Disease Followed by an up to 48-weeks Extension Period
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Tiomolibdate choline (Primary)
- Indications Hepatolenticular degeneration
- Focus Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease
Most Recent Events
- 16 Jul 2023 This trial has been completed in Germany (Global end date: 17 May 2023).
- 02 Jul 2023 This trial has been completed in France (Global end date: 17 May 2023).
- 01 Jul 2023 This trial has been completed in Denmark (Global end date: 17 May 2023)